Journal Article

Health economics study of paliperidone palmitate in the treatment of schizophrenia: a 12-month cohort study

Yang, Rucheng, Zhu, Xianrong, Xu, Xiufeng, Zhao, Yu, Sun, Zanzong, Lei, Ming, Lu, Jin, Huang, Liqiong, Wang, Yan, He, Shuhua, He, Xiaolin, Yang, Shunying, Li, Zhongcai, Cheng, Yuqi, Luo, Chuanlin, Gao, Changqing, Liu, Fang, Xie, Xian, Liu, Wei, Song, Jianhui, Luo, Xing, Zhang, Xi, Zhou, Yong, Wang, Jicai, Zhang, Lifen, Liu, Hong, Liu, Liming, He, Yuefei, Chen, Wenming, Wang, Bo, Wang, Tianlan, Xia, Yongbing, Ding, Hua, Gao, Donghua, Zhao, Jinkun, Gao, Chunqiang, Yang, Guangya, Pu, Ensheng

2024

Overview

Background To analyze the economic benefits of paliperidone palmitate in the treatment of schizophrenia. Methods We collected 546 patients who met the diagnostic criteria for schizophrenia according to the 《International Statistical Classification of Diseases and Related Health Problems,10th》(ICD-10). We gathered general population data such as gender, age, marital status, and education level, then initiated treatment with paliperidone palmitate. Then Follow-up evaluations were conducted at 1, 3, 6, 9, and 12 months after the start of treatment to assess clinical efficacy, adverse reactions, and injection doses. We also collected information on the economic burden before and after 12 months of treatment, as well as the number of outpatient visits and hospitalizations in the past year to analyze economic benefits. Results The baseline patients totaled 546, with 239 still receiving treatment with paliperidone palmitate 12 months later. After 12 months of treatment, the number of outpatient visits per year increased compared to before (4 (2,10) vs. 12 (4,12), Z=-5.949, P  < 0.001), while the number of hospitalizations decreased (1 (1,3) vs. 1 (1,2), Z = 5.625, P  < 0.001). The inpatient costs in the direct medical expenses of patients after 12 months of treatment decreased compared to before (5000(2000,12000) vs. 3000 (1000,8050), P  < 0.05), while there was no significant change in outpatient expenses and direct non-medical expenses (transportation, accommodation, meal, and family accompanying expenses, etc.) ( P  > 0.05); the indirect costs of patients after 12 months of treatment (lost productivity costs for patients and families, economic costs due to destructive behavior, costs of seeking non-medical assistance) decreased compared to before (300(150,600) vs. 150(100,200), P  < 0.05). Conclusion Palmatine palmitate reduces the number of hospitalizations for patients, as well as their direct and indirect economic burdens, and has good economic benefits.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Adult / Antipsychotic Agents - economics / Antipsychotic Agents - therapeutic use / Antipsychotics / Cohort analysis / Cohort Studies / Cost of Illness / Costs / Disease / Drug delivery systems / Drug dosages / Drug therapy / Drug withdrawal / Economic benefits / Education / Electrocardiography / Family medical history / Female / Gender / Hospitalization / Hospitalization - economics / Hospitalization - statistics & numerical data / Humans / Male / Marital status / Medical economics / Medicine / Medicine & Public Health / Mental disorders / Methods / Middle Aged / Missing data / Nervous system / Normal distribution / Paliperidone palmitate / Paliperidone Palmitate - administration & dosage / Paliperidone Palmitate - economics / Paliperidone Palmitate - therapeutic use / Palmitic acid / Patient compliance / Patient outcomes / Patients / Psychiatry / Psychotherapy / Psychotropic drugs / Questionnaires / Schizophrenia / Schizophrenia - drug therapy / Schizophrenia - economics / Substance abuse treatment / Suicides & suicide attempts / Treatment Outcome